Stock Market Today: Futures Rise After S&P 500, Nasdaq Close at Records; Chip Stocks Surge Further; Oil Prices Retreat

U.S. stock futures rose 0.3%-0.6% after the S&P 500 and Nasdaq hit fresh records, led by continued strength in chip stocks; Micron jumped 19% yesterday and was indicated another 7.5% higher, while Marvell gained 6.5% premarket ahead of earnings. Risk assets were mixed otherwise: Brent crude fell 2.6% to about $97, WTI dropped 3.5% to $90.55, the 10-year Treasury yield slipped below 4.48%, and gold declined 1.2% to $4,445. Standouts on the downside included Zscaler, down nearly 25% on a cautious outlook, and Insulet, down 5.5% on a medical device correction.

Analysis

The tape is being driven less by broad economic conviction and more by a narrow liquidity trade centered on AI-capex winners. That matters because when leadership compresses into a handful of semis and megacap momentum names, index-level upside can persist even as underlying breadth deteriorates — a setup that tends to reward being long the winners and selectively short the vulnerable second tier. The near-term implication is that flows, not fundamentals, remain the dominant marginal buyer.

The real second-order beneficiary is the semiconductor supply chain, not just the headline AI chip names. If hyperscaler spending is still being bid up, then equipment, advanced packaging, test, and foundry bottlenecks should keep pricing power longer than the market expects; the risk is that the trade starts to rotate from “growth at any price” into “capacity constraints and delivery schedules.” Conversely, software names with weaker switching costs are increasingly exposed to budget reprioritization as buyers funnel incremental spend into infrastructure rather than application-layer expansion.

The air pocket in ZS looks less like idiosyncratic earnings and more like a repricing of cyber premium multiples after several quarters of AI-related enterprise caution. That kind of de-rating often spills into adjacent high-multiple software if guides imply elongated sales cycles or tougher renewal math. PODD adds a different signal: product-quality issues can hit medtech names harder when investors are already willing to punish anything with execution risk, so the market is likely to pay up only for clean balance sheets and visible recurring demand.

The contrarian point is that the market may be underestimating how much the next wave of IPO supply can absorb marginal risk appetite, even if the index impact is modest. Supply shocks rarely break a bull market immediately, but they can cap multiple expansion and force rotation away from crowded names. The bigger reversal catalyst over the next 1-3 months is not macro data; it is whether earnings guidance starts confirming that AI spend is accelerating at the infrastructure layer while software demand stays restrained.

Key Decisions for Investors

• Long MRVL into earnings with a tactical 1-3 week horizon; use a defined-risk call spread or small outright long. Risk/reward favors upside continuation if guidance confirms AI demand durability, but trim quickly if management does not reinforce backlog visibility.
• Short ZS on any post-gap bounce over the next 3-5 sessions; target a 2-4 week mean reversion. The setup favors further multiple compression if peers echo cautious enterprise demand and the market rotates away from premium software.
• Pair long semis / short software: long MRVL or a semis basket versus short CRM or a software basket for 1-2 months. This expresses the view that capex is still outrunning application-layer spend, with upside if AI infrastructure spend remains the dominant budget line.
• Avoid chasing PODD until the correction narrative is quantified; wait for management to clarify scope and remediation timeline. If the issue proves contained, the stock can re-rate, but near-term skew is still to the downside given the market's low tolerance for execution risk.
• Maintain a small long TSLA as a momentum/flows expression, but treat it as a trading position, not a conviction hold. Upside is tied to continued index-level appetite for the Mag Seven, while the risk is rapid factor reversal if breadth stabilizes and crowded growth unwinds.